Balaji Prasad

Q: What is Balaji Prasad's success rate?

Balaji Prasad currently has a success rate of 100.

Barclays | Healthcare

Balaji Prasad is an analyst from Barclays specializing in the Healthcare sector. They are beginning to establish their track record, with 1 stock rating so far. Their current stats show a success rate of 100.00% and an average return of 0.00%.

Balaji Prasad has only issued 1 rating so far. While the sample size is small, their early calls show a success rate of 100.00% and an average return of 0.00%. Investors may find their initial activity in the Healthcare sector worth watching as they build a track record.

#2461

Out of 4773

Total Ratings

+100.00%

Success Rate

Average Return

Recent Ratings Analysis

EOLS

Buy

Mar 05, 2025

Target

$25.00

Current

$7.84

Performance

-44.67%

Balaji Prasad rated EOLS as Overweight on Mar 05, 2025, setting a price target of 25. The stock has underperformed, dropping 44.67% despite the bullish target of 25.

AMRX

Buy

Mar 03, 2025

Target

$11.00

Current

$17.01

Performance

94.18%

On Mar 03, 2025, AMRX was given a Overweight rating by Balaji Prasad, with a target price of 11. The stock rallied 94.18% after the rating, narrowing the gap to the target of 11 and validating the bullish stance.

PCRX

Buy

Feb 28, 2025

Target

$24.00

Current

$25.36

Performance

5.45%

PCRX received a Overweight rating from Balaji Prasad on Feb 28, 2025, aiming for 24. Momentum has favored the Buy call, with shares climbing from 25.36 to 25.36, rewarding those who trusted the recommendation.

VTRS

Sell

Feb 28, 2025

Target

$9.00

Current

$16.51

Performance

78.87%

On Feb 28, 2025, Balaji Prasad published a Underweight outlook on VTRS, with a target of 9. Investors who followed the Sell rating avoided losses as the stock weakened.

JAZZ

Buy

Feb 27, 2025

Target

$200.00

Current

$245.80

Performance

71.56%

Balaji Prasad on Feb 27, 2025 assigned JAZZ a Overweight rating, with a price target of 200. The Buy call aligned well with market performance, producing a gain of 71.56%.

TARS

Buy

Feb 26, 2025

Target

$60.00

Current

$79.31

Performance

86.35%

On Feb 26, 2025, Balaji Prasad reaffirmed TARS with a Overweight rating, targeting 60. The recommendation was supported by strong follow-through as the stock rose from 79.31 to 79.31.

ELAN

Buy

Feb 26, 2025

Target

$19.00

Current

$23.16

Performance

108.09%

ELAN was rated Overweight by Balaji Prasad on Feb 26, 2025, with a price objective of 19. A bullish response from the market helped close the gap of -4.16 to the target.

ZTS

Buy

Feb 14, 2025

Target

$244.00

Current

$73.00

Performance

-53.66%

On Feb 14, 2025, Balaji Prasad initiated coverage on ZTS with a Overweight rating and target of 244. The Buy call has yet to be validated as shares remain 171.00 away from the target.

OGN

Buy

Feb 14, 2025

Target

$24.00

Current

$13.64

Performance

-10.73%

Balaji Prasad issued a Overweight recommendation for OGN on Feb 14, 2025, price target set at 24. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

PAHC

Sell

Feb 10, 2025

Target

$22.00

Current

$35.62

Performance

35.85%

On Feb 10, 2025, PAHC was evaluated by Balaji Prasad, who gave a Underweight rating and target of 22. Investors benefited from heeding the Sell stance, avoiding a 35.85% decline.

IDXX

Buy

Feb 04, 2025

Target

$520.00

Current

$504.70

Performance

8.53%

Balaji Prasad rated IDXX as Overweight on Feb 04, 2025, setting a price target of 520. The call has proven timely, with shares rising 8.53% toward the price target of 520.

TEVA

Buy

Jan 30, 2025

Target

$26.00

Current

$37.09

Performance

107.90%

On Jan 30, 2025, TEVA was given a Overweight rating by Balaji Prasad, with a target price of 26. The stock rallied 107.90% after the rating, narrowing the gap to the target of 26 and validating the bullish stance.

RVNC

Hold

Dec 23, 2024

Target

$3.00

Current

$3.65

Performance

18.89%

RVNC received a Equal-Weight rating from Balaji Prasad on Dec 23, 2024, aiming for 3. Investors saw gains of 18.89% that the cautious stance didn’t fully capture.

LGND

Buy

Dec 16, 2024

Target

$160.00

Current

$284.47

Performance

132.52%

On Dec 16, 2024, Balaji Prasad published a Overweight outlook on LGND, with a target of 160. Shares gained 132.52%, underscoring the accuracy of the bullish outlook toward 160.

RDY

Buy

Jul 30, 2024

Target

$87.00

Current

$11.90

Performance

-26.22%

Balaji Prasad on Jul 30, 2024 assigned RDY a Overweight rating, with a price target of 87. The call has struggled to gain traction, with shares losing 26.22%.

ALVO

Buy

Jul 25, 2024

Target

$18.00

Current

$5.29

Performance

-53.14%

On Jul 25, 2024, Balaji Prasad reaffirmed ALVO with a Overweight rating, targeting 18. Shares slid 53.14% despite the recommendation, highlighting downside risks.

Frequency Asked Questions

Who is Balaji Prasad?

Balaji Prasad is an analyst from Barclays specializing in the Healthcare sector.

What is Balaji Prasad's success rate?

Balaji Prasad currently has a success rate of +100.00%.

How many ratings has Balaji Prasad issued?

Balaji Prasad has issued 1 stock ratings so far.

What is the average return of Balaji Prasad's calls?

Their stock ratings have generated an average return of 0.

What is Balaji Prasad's ranking?

Balaji Prasad is ranked #2461 out of 4773 analysts.

What types of ratings does Balaji Prasad give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Balaji Prasad?

You can follow Balaji Prasad by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Balaji Prasad?

Their latest rating was a Buy on EOLS issued on 2025-03-05.